Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) announced its earnings results on Monday. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.17 by ($0.03), Zacks reports. Shionogi & Co., Ltd. had a return on equity of 12.02% and a net margin of 35.53%. The firm had revenue of $721.77 million for the quarter, compared to the consensus estimate of $824.23 million.

Shionogi & Co., Ltd. Price Performance

OTCMKTS:SGIOY traded up $0.12 during midday trading on Friday, hitting $7.61. 110,070 shares of the stock were exchanged, compared to its average volume of 123,130. Shionogi & Co., Ltd. has a one year low of $6.22 and a one year high of $8.72. The company has a market capitalization of $12.95 billion, a price-to-earnings ratio of 14.55, a P/E/G ratio of 2.37 and a beta of 0.19. The business has a 50-day moving average price of $7.89 and a two-hundred day moving average price of $7.39. The company has a current ratio of 7.64, a quick ratio of 7.01 and a debt-to-equity ratio of 0.01.

About Shionogi & Co., Ltd.

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.